Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. develops oncology immunotherapies as a clinical-stage biotechnology company with American depositary shares traded under PPBT. Its recurring updates center on CAPTN-3, a platform of capped or masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells in the tumor microenvironment.
Company news commonly covers preclinical data, toxicology and manufacturing work for IM1240, the 5T4-targeting lead CAPTN-3 antibody, and IM1305, the TROP2-targeting development candidate. Other recurring themes include oncology research collaborations, scientific advisory activity, financial results, ADR and capital-structure actions, Nasdaq listing compliance, and governance updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.